reolysin
Biologicalexperimental
Pelareorep is a proprietary isolate of the unmodified human reovirus being developed as a systemically administered immuno-oncological viral agent for the treatment of solid tumors and hematological malignancies. Pelareorep is an oncolytic virus, which means that it preferentially lyses cancer cells. Pelareorep also promotes an inflamed tumor phenotype through innate and adaptive immune responses. Preliminary clinical trials indicate that it may have anti-cancer effects across a variety of cancer types when administered alone and in combination with other cancer therapies. — Wikipedia
Clinical trial activity
16 trials · 17 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
11
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2006 (NCT00528684)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Colorectal Neoplasms · Phase 2
- Fibrosarcoma · Phase 2
- Glioma · Phase 1
- Histiocytoma, Malignant Fibrous · Phase 2
- Leiomyosarcoma · Phase 2
- Lung Neoplasms · Phase 2
- Melanoma · Phase 2
- Multiple Myeloma · Phase 1
- Osteosarcoma · Phase 2
- Pancreatic Neoplasms · Phase 2
- Sarcoma, Ewing · Phase 2
- Sarcoma, Synovial · Phase 2
- Skin Neoplasms · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 3
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPelareorep ↗
Also known as
- reolysin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03282188 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2017 | University of Leeds, Yorkshire Cancer Research |
| NCT03015922 | Phase 1 | Jun 5, 2017 | Celgene, Myeloma UK, Oncolytics Biotech, University of Leeds |
| NCT02723838 | Phase 1 | Feb 28, 2017 | Oncolytics Biotech |
| NCT02620423 | Phase 1 | Dec 1, 2015 | Oncolytics Biotech, University of Texas, San Antonio |
| NCT01708993 | Phase 2 | Oct 15, 2012 | Canadian Cancer Trials Group, Oncolytics Biotech, University of Calgary |
| NCT01656538 | Phase 2 | Jul 30, 2012 | British Columbia Cancer Agency, Canadian Cancer Trials Group, Oncolytics Biotech |
| NCT01622543 | Phase 2 | Jun 11, 2012 | Canadian Cancer Trials Group, Oncolytics Biotech, University of Calgary, University of Ottawa |
| NCT01274624 | Phase 1 | Dec 1, 2010 | Oncolytics Biotech, Yeshiva University |
| NCT01166542 | Phase 3 | Jun 1, 2010 | Oncolytics Biotech, Royal Marsden Hospital NHS Trust, University of Alabama, Birmingham, University of Antwerp |
| NCT00998322 | Phase 2 | Oct 1, 2009 | Oncolytics Biotech, The University of Texas, Dallas |
| NCT00998192 | Phase 2 | Oct 1, 2009 | Cedars-Sinai Medical Center, Oncolytics Biotech, The University of Texas, Dallas |
| NCT00984464 | Phase 2 | Sep 1, 2009 | Oncolytics Biotech, The University of Texas, Dallas, University of Texas, San Antonio |
| NCT00861627 | Phase 2 | Mar 1, 2009 | Ohio State University, Oncolytics Biotech |
| NCT00753038 | Phase 2 | Aug 1, 2008 | Oncolytics Biotech |
| NCT00503295 | Phase 2 | Jun 1, 2007 | Oncolytics Biotech |
| NCT00528684 | Phase 1 | Jul 1, 2006 | Oncolytics Biotech, University of Alabama, Birmingham |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Oncolytics Biotech | For profit | 15 | 11 | 3 | 2006 |
| Canadian Cancer Trials Group | Academic/Hospital | 3 | 3 | 1 | 2012 |
| The University of Texas, Dallas | Academic/Hospital | 3 | 0 | 1 | 2009 |
| University of Alabama, Birmingham | Academic/Hospital | 2 | 0 | 2 | 2006 |
| University of Calgary | Academic/Hospital | 2 | 0 | 1 | 2012 |
| University of Leeds | Academic/Hospital | 2 | 2 | 2 | 2017 |
| University of Texas, San Antonio | Academic/Hospital | 2 | 0 | 2 | 2009 |
| British Columbia Cancer Agency | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Cedars-Sinai Medical Center | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Celgene | For profit | 1 | 0 | 1 | 2017 |
| Myeloma UK | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Antwerp | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Ottawa | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Yeshiva University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Yorkshire Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2017 |
17 organizations
Page 1 / 1